Phase 1 safety and tolerability trial of levodopa eye drops for the treatment of short sightedness (myopia)

This will be a first-in-human safety and tolerability trial of a novel ophthalmic solution for the treatment of the visual disorder myopia (short-sightedness). Myopia has been hypothesised to be driven by a reduction in dopamine levels within the eye. Therefore we have developed a novel ophthalmic formulation of a repurposed compound to stimulate ocular dopamine release. Before we can examine the efficacy of this compound at inhibiting myopia, this study will assess the safety and tolerability of levodopa as a reformulated eye drop solution.